Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer

Author： Maine Christian   Aziz Nor   Chatterjee Jayanta   Hayford Claudia   Brewig Nancy   Whilding Lynsey   George Andrew   Ghaem-Maghami Sadaf  

Publisher： Springer Publishing Company

ISSN： 0340-7004

Source： Cancer Immunology, Immunotherapy, Vol.63, Iss.3, 2014-03, pp. : 215-224

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand1 surface expression

By                    

Oncology Letters, Vol. 5, Iss. 5, 2013-01 ,pp. : 1519-1526

Spandidos Publications

Access to resources Recommend Favorite

ZBTB7 Overexpression Contributes to Malignancy in Breast Cancer

By Qu Hongyan   Qu Danni   Chen Fuhui   Zhang Zhenyu   Liu Baogang   Liu Haifeng  

Cancer Investigation, Vol. 28, Iss. 6, 2010-06 ,pp. : 672-678

Informa Healthcare

Access to resources Recommend Favorite

Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery

By                    

Oncology Letters, Vol. 10, Iss. 2, 2015-01 ,pp. : 1079-1086

Spandidos Publications

Access to resources Recommend Favorite

Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, Iss. 2, 2016-04 ,pp. : 141-151

Bentham Science Publishers

Access to resources Recommend Favorite

Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients

By Scartozzi M.   De Nictolis M.   Galizia E.   Carassai P.   Bianchi F.   Berardi R.   Gesuita R.   Piga A.   Cellerino R.   Porfiri E.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1144-1149

Elsevier

Access to resources Recommend Favorite